Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover

Trial Profile

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs ECCS 50 (Primary)
  • Indications Raynaud's disease; Scleroderma; Systemic scleroderma
  • Focus Registrational; Therapeutic Use
  • Acronyms STAR
  • Sponsors Cytori Therapeutics
  • Most Recent Events

    • 07 Nov 2017 Data presented in a Cytori Therapeutics Media Release.
    • 07 Nov 2017 According to a Cytori Therapeutics media release, full data analysis from this trial will be presented at 5th Systemic Sclerosis World Congress.
    • 24 Jul 2017 Top-line 24- and 48-week results published in a Cytori Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top